China’s NMPA Accepts EOC Pharma Group’s Filing for Vascepa (Icosapent Ethyl) for Review
The China-based EOC Pharma Group has achieved a significant milestone with the National Medical Products...
CVD
Hansoh Pharmaceutical’s HS-10511 Tablets for Hypertrophic Cardiomyopathy Cleared for Clinical Trials
Hansoh Pharmaceutical (HKG: 3692) has announced that its affiliated company’s self-developed Class 1 new drug,...
Novo Nordisk Commits Over DKK 42 Billion to Expand Chronic Disease Production in Denmark
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, last week announced a substantial plan to...
Sino Medical Sciences Technology Secures TFDA Approval for HT Supreme Drug-Eluting Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...
Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer based in...
MicroPort CardioFlow Medtech Completes Clinical Implantations of Second-Generation TAVI Device
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
BMS Regains Full Rights to Mavacamten in China and Asia from LianBio
Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment...
Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific
Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease...
Lepu Medical Gains NMPA Approval for Semi-Automatic External Defibrillator
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...
Novo Nordisk Strikes $1.3 Billion Deal for KBP Biosciences’ Ocedurenone
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) announced a significant deal this week, valued at...
Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...
Sino Medical Sciences’ HT Supreme Stent System Included in French Reimbursement List
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in China,...
Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases
Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...
Sino Medical Sciences Receives Turkish Approval for HT Supreme Drug-Eluting Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...
MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices
MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...
Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...
Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd, (HKG: 2291) a China-based medical technology company, has...
Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...
Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial
Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...
Novo Nordisk and Broad Institute Collaborate on Diabetes and Cardiometabolic Research
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a collaboration with the US academic...